ProCE Banner Activity

Phase Ib Venetoclax With Bortezomib and Dexamethasone Safe, Active in R/R MM

Slideset Download
Conference Coverage
Early study of venetoclax in combination with bortezomib/dexamethasone yields ORR in more than 80% of patients with R/R MM not refractory to bortezomib.

Released: June 09, 2016

Expiration: June 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals